EGFR and metastatic colorectal cancer: Furthermore, Strippoli et al. showed that alterations in the transcriptional factor c-MYC are involved in anti-EGFR resistance in metastatic colorectal cancer; patients with higher c-MYC expression showed a significantly lower PFS and OS when compared to those with low c-MYC expression [48].